SYNDESI THERAPEUTICS
The computed 12-month bankruptcy probability of SYNDESI THERAPEUTICS is 0.4% (very low). The company has been active since 2017 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
| Active | 8 yrs |
| Board | 4 |
| Locations | 1 |
| Publications | 23 |
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
| Fiscal year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | volledig | 08-06-2026 | 2026-00155848 |
| 31-12-2024 | volledig | 17-06-2025 | 2025-00153650 |
| 31-12-2023 | micro | 22-07-2024 | 2024-00271132 |
| 31-12-2022 | micro | 12-10-2023 | 2023-00486281 |
| 31-12-2021 | micro | 25-07-2022 | 2022-20217401 |
| 31-12-2020 | micro | 10-06-2021 | 2021-19600581 |
| 31-12-2019 | micro | 26-06-2020 | 2020-20700493 |
| 31-12-2018 | micro | 28-05-2019 | 2019-14500277 |
-
Current01-12-2025 → present
-
Current25-02-2022 → present
-
JCO Consulting SRLLegal entityDirector· perm. rep.: Jean CombalbertState Gazette act 21086769 (19-07-2021)Current19-07-2021 → present
-
AMRON NEUROSCIENCE LLCLegal entityDirector· perm. rep.: Roy Ervin TwymanState Gazette act 21086769 (19-07-2021)Current26-10-2018 → present
2 events
- 19-07-2021 Mandate renewed· Director
- 26-10-2018 Appointed· Director
Historic, not recently confirmed (1)
-
Not recently confirmedlast confirmed in an act from 2018
Former directors (9)
-
Former25-02-2022 → 01-12-2025
2 events
- 01-12-2025 Resigned· Director
- 25-02-2022 Appointed· Director
-
Former01-12-2022 → 21-11-2024
2 events
- 21-11-2024 Resigned· Director
- 01-12-2022 Appointed· Director
-
Former25-02-2022 → 01-12-2022
2 events
- 01-12-2022 Resigned· Director
- 25-02-2022 Appointed· Director
-
Former05-02-2018 → 25-02-2022
2 events
- 25-02-2022 Resigned· Director
- 05-02-2018 Appointed· Director
-
Former05-02-2018 → 25-02-2022
2 events
- 25-02-2022 Resigned· Director
- 05-02-2018 Appointed· Director
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| BDO Réviseurs d'Entreprises SCRLCurrent Statutory auditor · represented by Veerle Catry |
- | 19-07-2021 → present |
| NACE primary | Speur- en ontwikkelingswerk op biotechnologisch gebied(72101) |
| Legal form | Public limited company(014) |
| Incorporation | 19-12-2017 |
| Status | Active |
| Postal code | 1300 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25112N0041/00B000 | Wallonia | 1.5 ha | 1 · 832 m² | 21.3 m · 6 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
We know of 23 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
07-05-2026 Officer resignation · Officer appointment · Mandate compensation · Mandate term
- Filing: 2026-04-23 · Syndesi Therapeutics
- Publication: 2026-05-07 · Syndesi Therapeutics
- Officer resignation: date: 2026-04-01, role: administrateur · Rolfe van de Spreng
- Officer appointment: date: 2026-04-01, role: administrateur · Erica Silbiger
- Mandate compensation: amount: 0, currency: EUR · Erica Silbiger
- Mandate term: end_condition: assemblée générale ordinaire des actionnaires qui se tiendra en 2027 · Erica Silbiger
- Representation rule: un administrateur agissant seul · Syndesi Therapeutics
- Power of attorney: date: 2026-04-01, scope: signature des formulaires I, II et de tout autre document nécessaire en vue du dépôt et de la publication, granted_by: actionnaire unique · Nathalie Boonen
- Power of attorney: date: 2026-04-01, scope: signature des formulaires I, II et de tout autre document nécessaire en vue du dépôt et de la publication, granted_by: actionnaire unique · Jean-François Mouchet
- Act object: Démission et nomination d'un administrateur
Technical details
{
"facts": [
{
"type": "filing",
"quote": "23 AVR. 2026",
"value": "2026-04-23",
"object": null,
"subject": "e1"
},
{
"type": "publication",
"quote": "07/05/2026",
"value": "2026-05-07",
"object": null,
"subject": "e1"
},
{
"type": "officer_resignation",
"quote": "accept\u00E9 la d\u00E9mission de Rolfe van de Spreng \u00E0 compter du 1er avril 2026",
"value": {
"date": "2026-04-01",
"role": "administrateur"
},
"object": "e1",
"subject": "e2"
},
{
"type": "officer_appointment",
"quote": "nommer Erica Silbiger ... en qualit\u00E9 de nouvel administrateur de la Soci\u00E9t\u00E9, avec effet au 1er avril 2026",
"value": {
"date": "2026-04-01",
"role": "administrateur"
},
"object": "e1",
"subject": "e3"
},
{
"type": "mandate_compensation",
"quote": "Son mandat ne sera pas r\u00E9mun\u00E9r\u00E9",
"value": {
"amount": 0,
"currency": "EUR"
},
"object": "e1",
"subject": "e3"
},
{
"type": "mandate_term",
"quote": "prendra fin imm\u00E9diatement lors de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire des actionnaires qui se tiendra en 2027",
"value": {
"end_condition": "assembl\u00E9e g\u00E9n\u00E9rale ordinaire des actionnaires qui se tiendra en 2027"
},
"object": "e1",
"subject": "e3"
},
{
"type": "representation_rule",
"quote": "la Soci\u00E9t\u00E9 est valablement repr\u00E9sent\u00E9e ... par un administrateur agissant seul",
"value": "un administrateur agissant seul",
"object": null,
"subject": "e1"
},
{
"type": "power_of_attorney",
"quote": "l\u0027actionnaire unique a charg\u00E9 Nathalie Boonen ... de la signature des formulaires I, II et de tout autre document n\u00E9cessaire en vue du d\u00E9p\u00F4t et de la publication",
"value": {
"date": "2026-04-01",
"scope": "signature des formulaires I, II et de tout autre document n\u00E9cessaire en vue du d\u00E9p\u00F4t et de la publication",
"granted_by": "actionnaire unique"
},
"object": "e1",
"subject": "e4"
},
{
"type": "power_of_attorney",
"quote": "l\u0027actionnaire unique a charg\u00E9 ... Jean-Fran\u00E7ois Mouchet ... chacun agissant individuellement, de la signature des formulaires I, II et de tout autre document n\u00E9cessaire en vue du d\u00E9p\u00F4t et de la publication",
"value": {
"date": "2026-04-01",
"scope": "signature des formulaires I, II et de tout autre document n\u00E9cessaire en vue du d\u00E9p\u00F4t et de la publication",
"granted_by": "actionnaire unique"
},
"object": "e1",
"subject": "e5"
},
{
"type": "act_object",
"quote": "Objet de l\u0027acte: D\u00E9mission et nomination d\u0027un administrateur",
"value": "D\u00E9mission et nomination d\u0027un administrateur",
"object": null,
"subject": null
}
],
"act_meta": {
"model_id": 40,
"extractor": "open-capture-27b-v3",
"ocr_chars": 1977,
"truncated": false,
"needs_verify": false
},
"entities": [
{
"id": "e1",
"kbo": "0686.599.355",
"kind": "company",
"name": "Syndesi Therapeutics",
"attrs": {
"seat": "Avenue Einstein 14, 1300 Wavre",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
}
},
{
"id": "e2",
"kbo": null,
"kind": "person",
"name": "Rolfe van de Spreng",
"attrs": {}
},
{
"id": "e3",
"kbo": null,
"kind": "person",
"name": "Erica Silbiger",
"attrs": {}
},
{
"id": "e4",
"kbo": null,
"kind": "person",
"name": "Nathalie Boonen",
"attrs": {
"employer": "PwC Business Advisory Services SRL"
}
},
{
"id": "e5",
"kbo": null,
"kind": "person",
"name": "Jean-Fran\u00E7ois Mouchet",
"attrs": {
"employer": "PwC Legal SRL"
}
},
{
"id": "e6",
"kbo": null,
"kind": "org",
"name": "PwC Business Advisory Services SRL",
"attrs": {}
},
{
"id": "e7",
"kbo": null,
"kind": "org",
"name": "PwC Legal SRL",
"attrs": {}
}
]
}06-01-2026 1 director appointed, 1 resigning
- Rolfe van de Spreng, Bestuurder
- Jean-Antoine de Los Frailes, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean-Antoine de Los Frailes",
"address": null,
"birth_date": null
},
"effective_date": "2025-12-01",
"evidence_quote": "Il ressort des r\u00E9solutions prises par l\u0027actionnaire unique en date du 9 d\u00E9cembre 2025 que l\u0027actionnaire unique a accept\u00E9 la d\u00E9mission de M. Jean-Antoine de Los Frailes \u00E0 compter du 1ier d\u00E9cembre 2025."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Rolfe van de Spreng",
"address": null,
"birth_date": null
},
"effective_date": "2025-12-01",
"evidence_quote": "L\u0027actionnaire unique a nomm\u00E9 Rolfe van de Spreng, \u00E9lisant domicile au si\u00E8ge de la Soci\u00E9t\u00E9, en qualit\u00E9 de nouvel administrateur de la Soci\u00E9t\u00E9, avec effet au 1ier d\u00E9cembre 2025."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}23-12-2024 Scott Reents resigns as director
- Scott Reents, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Scott Reents",
"address": null,
"birth_date": null
},
"effective_date": "2024-11-21",
"evidence_quote": "Il ressort des r\u00E9solutions \u00E9crites prises par l\u0027actionnaire unique dd 26 novembre 2024 que l\u0027actionnaire unique a accept\u00E9 la d\u00E9mission de Monsieur Scott Reents \u00E0 compter du 21 novembre 2024."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}14-11-2024 EY Réviseurs d'Entreprises SRL appointed as statutory auditor
- EY Réviseurs d'Entreprises SRL, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "EY R\u00E9viseurs d\u0027Entreprises SRL",
"address": null,
"birth_date": null
},
"evidence_quote": "II ressort des r\u00E9solutions prises par l\u0027actionnaire unique en date du 28 octrobre 2024 que l\u0027actionnaire unique a d\u00E9cid\u00E9 de nommer la soci\u00E9t\u00E9 \u00AB EY R\u00E9viseurs d\u0027Entreprises SRL \u00BB (B00160), ayant son si\u00E8ge \u00E0 Kouterveldstraat 7B, 1831 Diegem, comme commissaire de la Soci\u00E9t\u00E9 pour un terme de trois ans, s"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}05-12-2023 Registered office moved from Louvain-La-Neuve to Wavre
- Chemin du Cyclotron 6, 1348 Louvain-La-Neuve → Avenue Einstein 14, 1300 Wavre
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Wavre",
"region": "Waals",
"street": "Avenue Einstein",
"country": "BE",
"postcode": "1300",
"box_number": null,
"street_number": "14"
},
"old_address": {
"city": "Louvain-La-Neuve",
"region": "Waals",
"street": "Chemin du Cyclotron",
"country": "BE",
"postcode": "1348",
"box_number": null,
"street_number": "6"
},
"effective_date": "2023-10-31",
"evidence_quote": "II ressort des r\u00E9solutions unanimes \u00E9crites des administrateurs en date du 19 novembre 2023 que les administrateurs ont d\u00E9cid\u00E9 de transf\u00E9rer le si\u00E8ge de la Soci\u00E9t\u00E9 et le si\u00E8ge d\u0027exploitation de Chemin du Cyclotron 6 1348 Louvain-La-Neuve \u00E0 Avenue Einstein 14, 1300 Wavre et ceci \u00E0 partir du 31 octobre 2023"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}03-01-2023 1 director appointed, 1 resigning
- Scott Reents, Bestuurder
- Robert Michael, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Robert Michael",
"address": null,
"birth_date": null
},
"effective_date": "2022-12-01",
"evidence_quote": "L\u0027actionnaire unique a pris connaissance de la demande de Monsieur Robert Michael d\u0027\u00EAtre d\u00E9charg\u00E9 de sa fonction d\u0027administrateur de la soci\u00E9t\u00E9 \u00E0 partir du 1er d\u00E9cembre 2022. L\u0027actionnaire unique accepte sa d\u00E9mission.",
"discharge_granted": true
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Scott Reents",
"address": null,
"birth_date": null
},
"effective_date": "2022-12-01",
"evidence_quote": "En vue de remplacer Monsieur Robert Michael, l\u0027actionnaire unique a d\u00E9cid\u00E9 de nommer Monsieur Scott Reents, \u00E9lisant domicile au si\u00E8ge de la soci\u00E9t\u00E9, comme nouvel administrateur de la soci\u00E9t\u00E9 \u00E0 partir du 1er d\u00E9cembre 2022."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}17-03-2022 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}10-03-2022 3 directors appointed, 7 resigning
- Jean-Antoine de Los Frailes, Bestuurder
- Renaud Jean-Louis Benjamin Decroix, Bestuurder
- Robert Michael, Bestuurder
- Jean Combalbert, Bestuurder
- Roy Ervin Twyman, Bestuurder
- Morten Graugaard Døssing, Bestuurder
- Aidan King, Bestuurder
- Emmanuel Lacroix, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean Combalbert",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0686599355",
"name": "JCO Consulting SRL",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2022-02-25",
"evidence_quote": "PAR CONS\u00C9QUENT, IL EST R\u00C9SOLU d\u0027accuser r\u00E9ception de la lettre de d\u00E9mission et d\u0027accepter la d\u00E9mission en tant qu\u0027administrateur de la Soci\u00E9t\u00E9, avec effet imm\u00E9diat, de chacun d\u0027entre eux: (a) JCO Consulting SRL, repr\u00E9sent\u00E9e de mani\u00E8re permanente par M. Jean Combalbert;"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Roy Ervin Twyman",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0686599355",
"name": "Amron Neuroscience LLC",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2022-02-25",
"evidence_quote": "PAR CONS\u00C9QUENT, IL EST R\u00C9SOLU d\u0027accuser r\u00E9ception de la lettre de d\u00E9mission et d\u0027accepter la d\u00E9mission en tant qu\u0027administrateur de la Soci\u00E9t\u00E9, avec effet imm\u00E9diat, de chacun d\u0027entre eux: (b) Amron Neuroscience LLC, repr\u00E9sent\u00E9e de mani\u00E8re permanente M. Roy Ervin Twyman;"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Morten Graugaard D\u00F8ssing",
"address": null,
"birth_date": null
},
"effective_date": "2022-02-25",
"evidence_quote": "PAR CONS\u00C9QUENT, IL EST R\u00C9SOLU d\u0027accuser r\u00E9ception de la lettre de d\u00E9mission et d\u0027accepter la d\u00E9mission en tant qu\u0027administrateur de la Soci\u00E9t\u00E9, avec effet imm\u00E9diat, de chacun d\u0027entre eux: (c) M. Morten Graugaard D\u00F8ssing;"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Aidan King",
"address": null,
"birth_date": null
},
"effective_date": "2022-02-25",
"evidence_quote": "PAR CONS\u00C9QUENT, IL EST R\u00C9SOLU d\u0027accuser r\u00E9ception de la lettre de d\u00E9mission et d\u0027accepter la d\u00E9mission en tant qu\u0027administrateur de la Soci\u00E9t\u00E9, avec effet imm\u00E9diat, de chacun d\u0027entre eux: (d) M. Aidan King;"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Emmanuel Lacroix",
"address": null,
"birth_date": null
},
"effective_date": "2022-02-25",
"evidence_quote": "PAR CONS\u00C9QUENT, IL EST R\u00C9SOLU d\u0027accuser r\u00E9ception de la lettre de d\u00E9mission et d\u0027accepter la d\u00E9mission en tant qu\u0027administrateur de la Soci\u00E9t\u00E9, avec effet imm\u00E9diat, de chacun d\u0027entre eux: (e) M. Emmanuel Lacroix;"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Fiona Maclaughlin",
"address": null,
"birth_date": null
},
"effective_date": "2022-02-25",
"evidence_quote": "PAR CONS\u00C9QUENT, IL EST R\u00C9SOLU d\u0027accuser r\u00E9ception de la lettre de d\u00E9mission et d\u0027accepter la d\u00E9mission en tant qu\u0027administrateur de la Soci\u00E9t\u00E9, avec effet imm\u00E9diat, de chacun d\u0027entre eux: (f) Mme Fiona Maclaughlin (n\u00E9e Mash);"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Christina Takke",
"address": null,
"birth_date": null
},
"effective_date": "2022-02-25",
"evidence_quote": "PAR CONS\u00C9QUENT, IL EST R\u00C9SOLU d\u0027accuser r\u00E9ception de la lettre de d\u00E9mission et d\u0027accepter la d\u00E9mission en tant qu\u0027administrateur de la Soci\u00E9t\u00E9, avec effet imm\u00E9diat, de chacun d\u0027entre eux: (g) Mme Christina Takke."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean-Antoine de Los Frailes",
"address": null,
"birth_date": null
},
"effective_date": "2022-02-25",
"evidence_quote": "IL EST EN OUTRE R\u00C9SOLU de nommer, avec effet imm\u00E9diat, comme administrateurs de la Soci\u00E9t\u00E9 qui exerceront leurs fonctions conform\u00E9ment aux statuts de la Soci\u00E9t\u00E9, jusqu\u0027\u00E0 la premi\u00E8re des deux dates suivantes: (a) le sixi\u00E8me anniversaire du pr\u00E9sent consentement \u00E9crit unanime, ou (b) leur d\u00E9mission ou "
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Renaud Jean-Louis Benjamin Decroix",
"address": null,
"birth_date": null
},
"effective_date": "2022-02-25",
"evidence_quote": "IL EST EN OUTRE R\u00C9SOLU de nommer, avec effet imm\u00E9diat, comme administrateurs de la Soci\u00E9t\u00E9 qui exerceront leurs fonctions conform\u00E9ment aux statuts de la Soci\u00E9t\u00E9, jusqu\u0027\u00E0 la premi\u00E8re des deux dates suivantes: (a) le sixi\u00E8me anniversaire du pr\u00E9sent consentement \u00E9crit unanime, ou (b) leur d\u00E9mission ou "
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Robert Michael",
"address": null,
"birth_date": null
},
"effective_date": "2022-02-25",
"evidence_quote": "IL EST EN OUTRE R\u00C9SOLU de nommer, avec effet imm\u00E9diat, comme administrateurs de la Soci\u00E9t\u00E9 qui exerceront leurs fonctions conform\u00E9ment aux statuts de la Soci\u00E9t\u00E9, jusqu\u0027\u00E0 la premi\u00E8re des deux dates suivantes: (a) le sixi\u00E8me anniversaire du pr\u00E9sent consentement \u00E9crit unanime, ou (b) leur d\u00E9mission ou "
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}07-03-2022 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": true,
"effective_date": "2022-02-25",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
},
"signature_regime": "solo",
"special_mandates": [
{
"quote": "une autorisation sp\u00E9ciale \u00E0 M. Axel Baet\u00E9, M. Toon Dictus et Mme Talitha Crabbe et \u00E0 chaque autre collaborateur ou assistant juridique de Cleary Gottlieb Steen \u0026 Hamilton LLP, \u00E9lisant domicile \u00E0 leur adresse professionnelle situ\u00E9e Rue de la Loi 57, 1040 Bruxelles, Belgique, chacun agissant seul et avec pouvoir de substitution, pour refl\u00E9ter les d\u00E9cisions prises par l\u0027assembl\u00E9e des actionnaires dans le registre des actionnaires et, dans la mesure requise, le registre des droits de souscription de la soci\u00E9t\u00E9 ainsi qu\u0027aupr\u00E8s de toutes les autorit\u00E9s fiscales, y compris en mati\u00E8re de \u0022 TVA \u0022, ainsi qu\u0027aupr\u00E8s du greffe du tribunal de l\u0027entreprise, de m\u00EAme qu\u0027aupr\u00E8s d\u0027un ou plusieurs guichets d\u0027affaires reconnus, afin d\u0027accomplir tous les actes, faire les d\u00E9clarations, signer et d\u00E9poser les documents requis pour l\u0027enregistrement, la signature et le d\u00E9p\u00F4t des documents n\u00E9cessaires \u00E0 l\u0027inscription, la modification ou la radiation de l\u0027inscription de la soci\u00E9t\u00E9 aupr\u00E8s de la Banque-Carrefour des Entreprises, et de mani\u00E8re g\u00E9n\u00E9rale, faire tout ce qui est n\u00E9cessaire ou utile \u00E0 l\u0027accomplissement de ces t\u00E2ches",
"holder_kbo": null,
"holder_name": "Cleary Gottlieb Steen \u0026 Hamilton LLP",
"scope_categories": [
"KBO",
"tax",
"filing",
"publication"
],
"with_substitution": true
}
],
"governance_change": {
"admin_delegated_added": []
}
}03-03-2022 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2022-02-25",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
},
"signature_regime": null,
"special_mandates": [
{
"quote": "Tous pouvoirs sont conf\u00E9r\u00E9s \u00E0 Christoph Michiels, Henri-Simon Vande Vyver, Jacques Bakulu et tout autre collaborateur de Deloitte Legal - Lawyers \u00E9lisant domicile dans le cadre du pr\u00E9sent acte \u00E0 Gateway Building, Luchthaven-Brussel-Nationaal 1J, 1930 Zaventem et \u00E0 chaque administrateur, afin de (i) supprimer les droits de souscription exerc\u00E9es du registre de droits de souscription, et (ii) inscrire les actions \u00E9mises suite \u00E0 l\u0027exercice de droits de souscription dans le registre des actions et de signer ce registre pour le compte des actionnaires en question.",
"holder_kbo": null,
"holder_name": "Deloitte Legal - Lawyers",
"scope_categories": [
"filing",
"register_maintenance"
],
"with_substitution": true
}
],
"governance_change": {
"admin_delegated_added": []
}
}19-07-2021 3 reappointed
- Jean Combalbert, Bestuurder
- Roy Ervin Twyman, Bestuurder
- Veerle Catry, Commissaris
Technical details
{
"events": [
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean Combalbert",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "JCO Consulting SRL",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de renouveler les mandats suivants: de JCO Consulting SRL, ayant son si\u00E8ge situ\u00E9 Cit\u00E9 du Sureau 7, Boite 1, 1000 Bruxelles, pour une p\u00E9riode de 3 ans, JCO Consulting SRL a d\u00E9sign\u00E9 Jean Combalbert en tant que repr\u00E9sentant permanant."
},
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Roy Ervin Twyman",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "AMRON NEUROSCIENCE LLC",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de renouveler les mandats suivants: AMRON NEUROSCIENCE LLC, ayant son si\u00E8ge situ\u00E9 \u00E0 745 Lake Como Road Darby Montana Montana, Etats-Unis d\u0027Am\u00E9rique, pour une p\u00E9riode de 3 ans. AMRON NEUROSCIENCE LLC a d\u00E9sign\u00E9 Roy Ervin Twyman en tant que repr\u00E9sentant permanant."
},
{
"kind": "commissaris_renew",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Veerle Catry",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "BDO R\u00E9viseurs d\u0027Entreprises SCRL",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de renouveler le mandat du commissaire, BDO R\u00E9viseurs d\u0027Entreprises SCRL, pour une p\u00E9riode de trois ans dont le premier exercice est 2021. Cette soci\u00E9t\u00E9 a d\u00E9sign\u00E9 Veerle Catry, reviseur d\u0027entreprises, charg\u00E9e de l\u0027exercice de son mandat."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}03-06-2021 Capital increase of €6,000,000 to €24,222,599.83
- €18.222.599,83 → €24.222.599,83
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 6000000.0,
"currency": "EUR",
"after_eur": 24222599.83,
"delta_eur": 6000000.0,
"before_eur": 18222599.83,
"amount_type": "kapitaal_effectief",
"effective_date": "2021-05-17",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital de la Soci\u00E9t\u00E9 \u00E0 concurrence de 6.000.000,00 EUR, pour le porter de 18.222.599,83 EUR \u00E0 24.222.599,83 EUR.",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}09-10-2020 1 director appointed, 1 resigning
- Fiona MacLaughlin, Bestuurder
- Jeanne Bolger, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jeanne Bolger",
"address": null,
"birth_date": null
},
"effective_date": "2020-09-30",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de: 1. prendre acte de la d\u00E9mission de Madame Jeanne Bolger en tant qu\u0027administrateur de la Soci\u00E9t\u00E9, qui prend effet au 30 septembre 2020."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Fiona MacLaughlin",
"address": null,
"birth_date": null
},
"effective_date": "2020-09-30",
"evidence_quote": "2. Nommer Madame Fiona MacLaughlin (n\u00E9e Mash), domicili\u00E9e \u00E0 2 Lavenham Road, Londres SW18 5\u041D\u0410. Royaume-Uni, en tant qu\u0027administrateur de la Soci\u00E9t\u00E9 \u00E0 partir du 30 septembre 2020."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}30-06-2020 Capital increase of €5,950,006.85 to €18,220,632.06
- €12.270.625,21 → €18.220.632,06
- 2 kapitaalbewegingen in deze akte
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 5950006.85,
"currency": "EUR",
"after_eur": 18220632.06,
"delta_eur": 5950006.85,
"before_eur": 12270625.21,
"amount_type": "kapitaal_effectief",
"effective_date": "2020-06-19",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital de la Soci\u00E9t\u00E9 \u00E0 concurrence de 5.950.006,85 EUR, pour le porter de 12.270.625,21 EUR \u00E0 18.220.632,06 EUR.",
"contribution_type": "cash"
},
{
"kind": "capital_increase",
"amount": 1967.77,
"currency": "EUR",
"after_eur": 18222599.83,
"delta_eur": 1967.77,
"before_eur": 18220632.06,
"amount_type": "kapitaal_effectief",
"effective_date": "2020-06-19",
"evidence_quote": "Le capital a \u00E9t\u00E9 augment\u00E9 \u00E0 concurrence de 1.967,77 EUR, de sorte que le capital sera augment\u00E9 de 18.220.632,06 EUR \u00E0 18.222.599,83 EUR;",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}30-01-2020 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}13-09-2019 Bolger Jeanne appointed as director
- Bolger Jeanne, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Bolger Jeanne",
"address": null,
"birth_date": null
},
"effective_date": "2019-07-31",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de nommer Mme Jeanne Bolger en tant qu\u0027administrateur de la soci\u00E9t\u00E9 sur base d\u0027une liste de candidats propos\u00E9s par JJDC, pour une p\u00E9riode de 6 ans \u00E0 partir du 31 juillet 2019."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}25-04-2019 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2018-12-19",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}10-01-2019 Capital increase of €5,525,021.13 to €12,268,798
- €6.743.776,87 → €12.268.798
- 2 kapitaalbewegingen in deze akte
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 5525021.13,
"currency": "EUR",
"after_eur": 12268798.0,
"delta_eur": 5525021.13,
"before_eur": 6743776.87,
"amount_type": "kapitaal_effectief",
"effective_date": "2018-12-19",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital de la Soci\u00E9t\u00E9 \u00E0 concurrence de \u20AC 5.525.021,13, pour le porter de \u20AC 6.743.776,87 \u00E0 \u20AC 12.268.798,00.",
"contribution_type": "cash"
},
{
"kind": "capital_increase",
"amount": 1827.21,
"currency": "EUR",
"after_eur": 12270625.21,
"delta_eur": 1827.21,
"before_eur": 12268798.0,
"amount_type": "kapitaal_effectief",
"effective_date": "2018-12-19",
"evidence_quote": "Le capital a \u00E9t\u00E9 augment\u00E9 \u00E0 concurrence \u20AC 1.827,21, de sorte que le capital sera augment\u00E9 de \u20AC 12.268.798,00 \u00E0 \u20AC 12.270.625,21;",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}26-10-2018 Roy Ervin Twyman appointed as director
- Roy Ervin Twyman, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Roy Ervin Twyman",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Amron Neuroscience LLC",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "Amron Neuroscience LLC, ayant son si\u00E8ge social \u00E0 745 Lake Como Road, Darby, MT 59829 USA repr\u00E9sent\u00E9e par Monsieur Roy Ervin Twyman est nomm\u00E9 comme administrateur ind\u00E9pendant de la soci\u00E9t\u00E9 sur base d\u0027une liste de candidats propos\u00E9s par Conseil d\u0027administration conform\u00E9ment \u00E0 l\u0027article 9 des statuts d"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}11-06-2018 2 directors appointed
- Jean Combalbert, Bestuurder
- Veerle Catry, Commissaris
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean Combalbert",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0686599355",
"name": "JCO Consulting SPRL",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "JCO Consulting SPRL, ayant son si\u00E8ge social \u00E0 1000 Bruxelles, Cit\u00E9 du Sureau 7, Belgique repr\u00E9sent\u00E9e par Monsieur Jean Combalbert est nomm\u00E9 comme admin\u00EDstrateur ind\u00E9pendant de la Soci\u00E9t\u00E9 sur base d\u0027une liste de candidats propos\u00E9s par la SRIW pour une dur\u00E9e de trois ans."
},
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Veerle Catry",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0686599355",
"name": "BDO Bedrijfsrevisoren Burg. Ven. CVBA - BDO R\u00E9viseurs d\u0027Entreprises Soc. Civ. SCRL",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "BDO Bedrijfsrevisoren Burg. Ven. CVBA - BDO R\u00E9viseurs d\u0027Entreprises Soc. Civ. SCRL, ayant son si\u00E8ge social \u00E0 1935 Zaventem, Elsinore Building, Corporate Village, Da Vincilaan 9/E6, repr\u00E9sent\u00E9e par Mme Veerle Catry est nomm\u00E9 comme commissaire de la Soci\u00E9t\u00E9 pour une dur\u00E9e de 3 ans, prenant fin imm\u00E9dia"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}20-02-2018 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}05-02-2018 4 directors appointed
- Døssing Morton Graugaard, Bestuurder
- King Aidan, Bestuurder
- LACROIX Emmanuel, Bestuurder
- Takke Christina, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "D\u00F8ssing Morton Graugaard",
"address": null,
"birth_date": null
},
"evidence_quote": "L\u0027assembl\u00E9e nomme les personnes suivantes en tant qu\u0027administrateurs de la soci\u00E9t\u00E9 : 1. Comme administrateur nomm\u00E9 sur base d\u0027une liste de candidats propos\u00E9s par Novo : Monsieur Morton Graugaard D\u00F8ssing, avec adresse professionnelle \u00E0 Tuborg Havnevej 19, 2900 Hellerup, Danmark;"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "King Aidan",
"address": null,
"birth_date": null
},
"evidence_quote": "1.Comme administrateur nomm\u00E9 sur base d\u0027une liste de candidats propos\u00E9s par Fountain: Aidan King, avec adresse professionnelle \u00E0 Fountain Healthcare Partners, Guild House, 4th Floor, Guild St., IFSC, Dublin 1, Irelande:"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "LACROIX Emmanuel",
"address": null,
"birth_date": null
},
"evidence_quote": "2.Comme administrateur nomm\u00E9 sur base d\u0027une liste de candidats propos\u00E9s par UCB: Monsieur LACROIX Emmanuel, avec adresse professionnelle \u00E0 1070 Anderlecht (Bruxelles), all\u00E9e de la Recherche 60;"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Takke Christina",
"address": null,
"birth_date": null
},
"evidence_quote": "3.Comme administrateur nomm\u00E9 sur base d\u0027une liste de candidats propos\u00E9s par V-Bio: Madame Christina Takke, avec adress pr\u00EDv\u00E9e \u00E0 Feike de Boerlaan 14, 1019MN Amsterdam, Pays-Bas;"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SA"
}
}21-12-2017 Incorporation of a new SNC
Technical details
{
"kind": "oprichting",
"seat": "1348 Ottignies-Louvain-la-Neuve, chemin du Cyclotron 6",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": "0403.053.068",
"name": "UCB BIOPHARMA"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": "0403.053.068",
"holder_org_name": "UCB BIOPHARMA",
"contribution_type": "in_kind",
"amount_paid_in_eur": 0.0,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 182721,
"amount_subscribed_eur": 3750000.0,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": "0403.198.811",
"name": "UCB FIPAR"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": "0403.198.811",
"holder_org_name": "UCB FIPAR",
"contribution_type": "cash",
"amount_paid_in_eur": 20.52,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 1,
"amount_subscribed_eur": 20.52,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 1218755.74,
"subject_company": {
"kbo": "0686.599.355",
"name_full": "SYNDESI THERAPEUTICS",
"legal_form": "SNC"
},
"initial_directors": [],
"incorporation_date": "2017-12-18",
"post_incorporation_mandates": []
}| Legal nameFR | SYNDESI THERAPEUTICS |